Meta-analysis: Proton pump inhibitor use and the risk of community-acquired pneumonia

Alimentary Pharmacology and Therapeutics

Volumn 31, Issue 11, 2010, Pages 1165-1177

  Johnstone, J ^a,b   Nerenberg, K ^a   Loeb, M ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIULCER AGENT; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ARTICLE; ASPIRATION PNEUMONIA; CASE CONTROL STUDY; CINAHL; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONFIDENCE INTERVAL; DRUG USE; EMBASE; GASTROINTESTINAL HEMORRHAGE; HUMAN; INFECTION RISK; INFORMATION RETRIEVAL; MEDLINE; META ANALYSIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OUTPATIENT; PRIORITY JOURNAL; RISK ASSESSMENT; STRESS ULCER; SYSTEMATIC REVIEW; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-ULCER AGENTS; CASE-CONTROL STUDIES; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMONIA; PROTON PUMP INHIBITORS; RISK FACTORS; YOUNG ADULT;

EID: 77951780214     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04284.x     Document Type: Article

References (54)

1. Leontiadis G, Sharma V, Howden C. Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev 2006 : CD002094.
2. Ford A, Delaney B, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev 2006 : CD003840.
3. van Pinxteren B, Numans M, Bonis P, Lau J. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2006 : CD002095.
4. Moayyedi P, Santana J, Khan M, Preston C, Donnellan C. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev 2007 : CD003244.
5. Donnellan C, Preston C, Moayyedi P, Sharma N. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2004 : CD003245.
6. Delaney B, Ford A, Forman D, Moayyedi P, Qume M. Initial management strategies for dyspepsia. Cochrane Database Syst Rev 2005 : CD001961.
7. Moayyedi P, Deeks JJ, Delaney B, Innes M, Forman D. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006 : CD001960.
8. Cote GA, Howden CW. Potential adverse effects of proton pump inhibitors. Curr Gastroenterol Rep 2008 10 : 208 214.
9. Esplugues J, Marti-Cabrera M, Ponce J. Safety of proton pump inhibitors. Med Clin 2006 127 : 790 795.
10. Ho P, Maddox T, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009 301 : 937 944.
11. Juurlink D, Gomes T, Ko D, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009 180 : 713 718.
12. Pham CQD, Sadowski-Hayes LM, Regal RE. Prevalent prescribing of proton pump inhibitors: prudent or pernicious? Pharm Ther 2006 31 : 159 167.
13. Leonard J, Marshall J, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007 102 : 2047 2056.
14. Yang Y, Lewis J, Epstein S, Metz D. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006 296 : 2947 2953.
15. Laheij R, Sturkenboom M, Hassing R, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004 292 : 1955 1960.
16. Gulmez SE, Holm A, Frederiksen H, et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 2007 167 : 950 955.
17. Sarkar M, Hennessy S, Yang YX, et al. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med 2008 149 : 391 398.
18. Myles PR, McKeever TM, Pogson Z, Smith CJ, Gibson JE. Risk of community-acquired pneumonia and the use of statins, ace inhibitors and gastric acid suppressants: a population-based case-control study. Pharmacoepidemiol Drug Saf 2009 18 : 269 275.
19. Rodriguez L, Ruigomez A, Wallander M, Johansson S. Acid-suppressive drugs and community-acquired pneumonia. Epidemiol 2009 20 : 800 806.
20. Eurich D, Sadowski CA, Simpson S, et al. Recurrent community-acquired pneumonia in patients starting acid-suppressing drugs. Am J Med 2010 123 : 47 53.
21. Roughead E, Ramsay E, Pratt N, Ryan P, Gilbert A. Proton-pump inhibitors and the risk of antibiotic use and hospitalization for pneumonia. Med J Aust 2009 190 : 114 116.
22. Sultan N, Nazareno J, Gregor J, et al. Association between proton pump inhibitors and respiratory infections: a systematic review and meta-analysis of clinical trials. Can J Gastroenterol 2008 22 : 761 766.
23. Estborn L, Joelson S, Estborn L, Joelson S. Occurrence of community-acquired respiratory tract infection in patients receiving esomeprazole: retrospective analysis of adverse events in 31 clinical trials. Drug Saf 2008 31 : 627 636.
24. Higgins J, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions: The Cochrane Collaboration. Wiley-Blackwell
25. Marchetti F, Gerarduzzi T, Ventura A. Proton pump inhibitors in children: a review. Dig Liver Dis 2003 35 : 738 746.
26. Mandell L, Wunderink R, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007 44 (Suppl 2 S27 72.
27. Niederman M, Craven D, Bonten M, et al. Guidelines for the management of adults with hospital acquired, ventilator associated, and healthcare associated pneumoinia. Am J Crit Car Med 2005 171 : 388 416.
28. Committee for the Japanese Respiratory Society Guidelines in Management of Respiratory. Pneumonia in immunosuppressed patients. Respirology 2004 9 (Suppl 1 S25 9.
29. Hunt R, Fallone C, van Zanten S, et al. Canadian Helicobacter Study Group Consensus Conference: update on the management of Helicobacter pylori - an evidence-based evaluation of six topics relevant to clinical outcomes in patients evaluated for H. pylori infection. Can J Gastroenterol 2004 18 : 547 554.
30. Fleiss J. The statistical basis of meta-analysis. Stat Methods Med Res 1993 2 : 121 145.
31. Buscemi N, Hartling L, Vandermeer B, et al. Single data extraction generated more errors than double data extraction in systematic reviews. J Clin Epidemiol 2006 59 : 687 703.
32. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986 7 : 177 188.
33. Hellström P, Vitols S. The choice of proton pump inhibitor: does it matter? Basic Clin Pharmacol Toxicol 2004 94 : 106 111. (Pubitemid 38419848)
34. Klok R, Postma M, van Hout B, Brouwers J. Meta-analysis: comparing the efficacy of proton pump inhibitors in short-term use. Aliment Pharmacol Ther 2003 17 : 1237 1245.
35. Higgins J, Thompson S, Deeks J, Altman D. Measuring inconsistency in meta-analyses. BMJ 2003 327 : 557 560.
36. Altman D, Bland J. Interaction revisited: the difference between two estimates. BMJ 2003 326 : 219.
37. File T Jr. Community-acquired pneumonia. Lancet 2003 362 : 1991 2001.
38. Loeb M, Neupane B, Walter S, et al. Environmental risk factors for community- acquired pneumonia hospitalization in older adults. J Am Geriatr Soc 2009 57 : 1036 1040.
39. Jackson M, Nelson J, Jackson L. Risk factors for community-acquired pneumonia in immunocompetent seniors. J Am Geriatr Soc 2009 57 : 882 888.
40. Marik P. Aspiration pneumonitis and aspiration pneumonia. N Engl J Med 2001 344 : 665 671.
41. van de Garde EM, Souverein PC, Hak E, et al. Angiotensin-converting enzyme inhibitor use and protection against pneumonia in patients with diabetes. J Hypertens 2007 25 : 235 239.
42. van de Garde E, Souverein P, van den Bosch J, et al. Angiotensin- converting enzyme inhibitor use and pneumonia risk in a general population. Eur Respir J 2006 27 : 1217 1222.
43. Knol W, Van Marum RJ, Jansen PAF, et al. Antipsychotic drug use and risk of pneumonia in elderly people. J Am Geriatr Soc 2008 56 : 661 666.
44. Laheij RJ, Van Ijzendoorn MC, Janssen MJ, et al. Gastric acid-suppressive therapy and community-acquired respiratory infections. Aliment Pharmacol Ther 2003 18 : 847 851.
45. Joelson S, Joelson IB, Lundborg P, et al. Safety experience from long-term treatment with omeprazole. Digestion 1992 51 (Suppl 1 S93 101.
46. Sanderson S, Tatt I, Higgins J. Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography. Int J Epidemiol 2007 36 : 666 676.
47. von Elm E, Altman D, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. PLOS Med 2007 4 : 1623 1627. (Pubitemid 350035453)
48. Horwitz R, Feinstein A. The problem of protopathic bias in case-control studies. Am J Med 1980 68 : 255 258.
49. Callreus T. The precautionary principle and pharmaceutical risk management. Drug Saf 2006 28 : 465 471.
50. Torres A, El-Ebiary M, Solar N, et al. Stomach as a source of colonization of the respiratory tract during mechanical ventilation: association with ventilator- associated pneumonia. Eur Respir J 1996 9 : 1729 1735.
51. Williams C, McColl K. Proton pump inhibitors and bacterial overgrowth. Aliment Pharmacol Ther 2006 23 : 3 10.
52. Nealis TB, Howden CW. Is there a dark side to long-term proton pump inhibitor therapy? Am J Ther 2008 15 : 536 542.
53. Zedtwitz-Liebenstein K, Wenisch C, Partruata S, et al. Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med 2002 30 : 1118 1122.
54. Aybay C, Imir T, Okur H. The effect of omeprazole on human natural killer cells. Gen Pharmacol 1995 26 : 1413 1418.